Position statement: AI-induced bone loss in postmenopausal breast cancer

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • Bone fracture risk should be assessed in all postmenopausal patients with breast cancer starting aromatase inhibitor (AI) treatment.
  • Bone-directed therapy should be given to all patients with a T-score of <−2.0 or with a T-score of <1.5 SD with one extra risk factor besides low bone mineral density (BMD), according to a joint statement of 6 medical societies.
Why this matters
  • Based on the newest evidence, fracture incidence in patients on A...